The US Food and Drug Administration (FDA) has granted approval to nogapendekin alfa inbakicept-pmln (Anktiva, Altor BioScience)—an interleukin-15 receptor agonist—with bacillus Calmette-Guérin (BCG) for adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. Approval came following results of the QUILT-3.032 trial, a single-arm study of 77 patients with BCG-unresponsive, high-risk NMIBC with CIS with or without Ta/T1 papillary disease who had undergone transurethral resection and went on to receive nogapendekin alfa inbakicept-pmln with BCG followed by maintenance therapy for up to 37 months. ...
Non-Muscle Invasive Urothelial Carcinoma
Advertisement
Latest News
Dr. Joshi contextualizes the THOR study within the treatment landscape for FGFR2/3-altered advanced urothelial carcinoma.
Ferring Pharmaceuticals has expanded their Adstiladrin clinical trial program to include 3 new studies in NMIBC.
The FDA has accepted the Investigational New Drug Application for UGN-103 for low-grade intermediate-risk NMIBC.
Dr. Myers and colleagues challenge the current paradigm of discouraging additional BCG therapy for "unresponsive" NMIBC.
Some patients who meet the FDA criteria for “BCG-unresponsive” bladder cancer may benefit from additional BCG therapy.
Dr. Ferguson highlights the latest TAR-210 and TAR-200 data in select patients with non-muscle invasive bladder cancer.
Advertisement
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Dr. Miles-Thomas shares the challenges of female urology and her vision for her tenure as AUA treasurer.
Dr. Afari elaborates on the factors he identified that contribute to renal function improvement post-partial nephrectomy.
Dr. Galsky shares the first OS data update on the CheckMate 274 trial, which he gave at the 2024 EAU Congress.
Dr. Julian Chavarriaga describes his study on using miRNA as a liquid biomarker to detect malignancy in testicular masses.
Dr. Finati discusses what the future has in store for further investigation utilizing larger patient databases.
Drs. Grasso and Verhovsky discuss the potential of endoscopic treatment with surveillance for patients with bladder cancer.
Advertisement
Advertisement
Latest News
Patients underwent treatment with lenvatinib plus everolimus as a second-line therapy.
An analysis of the phase 3 ARASENS study revealed new information on PSA responses and their association with outcomes.
A review analyzed 30 meta-analyses to determine the association between pretreatment NLR and immunotherapy outcomes.
